1-10 of 10
Bhumsuk Keam
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Transcriptomic Heterogeneity of EGFR-Mutant Non–Small Cell Lung Cancer Evolution Toward Small-Cell Lung Cancer

Songji Oh, Jaemoon Koh, Tae Min Kim, Soyeon Kim, Jeonghwan Youk, Miso Kim, Bhumsuk Keam, Yoon Kyung Jeon, Ja-Lok Ku, Dong-Wan Kim, Doo Hyun Chung, Dae Seog Heo
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (20): 4729–4742.
https://doi.org/10.1158/1078-0432.CCR-24-0160
Published: 15 October 2024
View article titled, Transcriptomic Heterogeneity of <em>EGFR</em>-Mutant Non–Small Cell Lung Cancer Evolution Toward Small-Cell Lung Cancer
Open the PDF for Transcriptomic Heterogeneity of <em>EGFR</em>-Mutant Non–Small Cell Lung Cancer Evolution Toward Small-Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer

Hans Prenen, Sanjeev Deva, Bhumsuk Keam, Colin R. Lindsay, Iwona Lugowska, James C. Yang, Federico Longo, Maria de Miguel, Mariano Ponz-Sarvise, Myung-Ju Ahn, Mahmut Gumus, Stephane Champiat, Antoine Italiano, Sébastien Salas, Ruth Perets, Cagatay Arslan, Byoung C. Cho, Stefan Evers, Christophe Boetsch, Daniel Marbach, David Dejardin, Nassim Sleiman, Caroline Ardeshir, Muriel Richard, Jehad Charo, Anton Kraxner, Nino Keshelava, Volker Teichgräber, Victor Moreno
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (14): 2945–2953.
https://doi.org/10.1158/1078-0432.CCR-23-2677
Published: 15 July 2024
View article titled, Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer
Open the PDF for Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

Glenn J. Hanna, Myung-Ju Ahn, Jameel Muzaffar, Bhumsuk Keam, Daniel W. Bowles, Deborah J. Wong, Alan L. Ho, Sung-Bae Kim, Francis Worden, Tak Yun, Xianzhang Meng, Jan M. Van Tornout, Maureen G. Conlan, Hyunseok Kang
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (22): 4555–4563.
https://doi.org/10.1158/1078-0432.CCR-23-1030
Published: 14 November 2023
View article titled, A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma
Open the PDF for A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma in another window
Includes: Supplementary data
Journal Articles

A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17–11)

Hyun Ae Jung, Keon-Uk Park, Sanghee Cho, Jinyeong Lim, Keun-Wook Lee, Min Hee Hong, Tak Yun, Ho Jung An, Woong-Yang Park, Sergio Pereira, Chan-Young Ock, Bhumsuk Keam
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (19): 4240–4247.
https://doi.org/10.1158/1078-0432.CCR-22-1238
Published: 03 October 2022
View article titled, A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17–11)
Open the PDF for A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17–11) in another window
Includes: Supplementary data
Journal Articles

Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma

Eun Joo Kang, Myung-Ju Ahn, Chan-Young Ock, Keun-Wook Lee, Jung Hye Kwon, Yaewon Yang, Yoon Hee Choi, Min Kyoung Kim, Jun Ho Ji, Tak Yun, Byung-Ho Nam, Sung-Bae Kim, Bhumsuk Keam
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5272–5279.
https://doi.org/10.1158/1078-0432.CCR-21-1061
Published: 01 October 2021
View article titled, Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma
Open the PDF for Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma in another window
Journal Articles

Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors

Bonnie S. Glisson, Rom S. Leidner, Robert L. Ferris, John Powderly, Naiyer A. Rizvi, Bhumsuk Keam, Reva Schneider, Sanjay Goel, James P. Ohr, Jennifer Burton, Yanan Zheng, Steven Eck, Matthew Gribbin, Katie Streicher, Danielle M. Townsley, Sandip Pravin Patel
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (20): 5358–5367.
https://doi.org/10.1158/1078-0432.CCR-19-3070
Published: 15 October 2020
View article titled, Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors
Open the PDF for Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy

Padmanee Sharma, Joohyuk Sohn, Sang Joon Shin, Do-Youn Oh, Bhumsuk Keam, Hyo Jin Lee, Marco Gizzi, Ewa Kalinka, Filip Y.F.L. de Vos, Dario Ruscica, Salvatore Ferro, Feng Xiao, Paul Baverel, Cecil Chi-Keung Chen, Kobby Asubonteng, Nassim Morsli, Luc Dirix
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (1): 61–70.
https://doi.org/10.1158/1078-0432.CCR-19-1635
Published: 03 January 2020
View article titled, Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy
Open the PDF for Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy in another window
Includes: Supplementary data
Journal Articles

Abstract B27: Osimertinib (AZD9291) is sensitive and bound with affinity to EGFR exon 20 insertion mutant models

Yusoo Lee, Tae Min Kim, Dong-Wan Kim, Yong-Oon Ahn, Soyeon Kim, Bhumsuk Keam, Miso Kim, Dae Seog Heo
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (17_Supplement): B27.
https://doi.org/10.1158/1557-3265.AACRIASLC18-B27
Published: 01 September 2018
View article titled, Abstract B27: Osimertinib (AZD9291) is sensitive and bound with affinity to <em>EGFR</em> exon 20 insertion mutant models
Journal Articles

Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration

Chan-Young Ock, Bhumsuk Keam, Sehui Kim, Ju-Seog Lee, Miso Kim, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Doo Hyun Chung, Dae Seog Heo
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (9): 2261–2270.
https://doi.org/10.1158/1078-0432.CCR-15-2834
Published: 01 May 2016
View article titled, Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration
Open the PDF for Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration in another window
Includes: Supplementary data
Journal Articles

Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non–Small Cell Lung Cancer

Ahnah Song, Tae Min Kim, Dong-Wan Kim, Soyeon Kim, Bhumsuk Keam, Se-Hoon Lee, Dae Seog Heo
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (10): 2379–2387.
https://doi.org/10.1158/1078-0432.CCR-14-1350
Published: 14 May 2015
View article titled, Molecular Changes Associated with Acquired Resistance to Crizotinib in <em>ROS1</em>-Rearranged Non–Small Cell Lung Cancer
Open the PDF for Molecular Changes Associated with Acquired Resistance to Crizotinib in <em>ROS1</em>-Rearranged Non–Small Cell Lung Cancer in another window
Includes: Supplementary data